KR102900433B1 - 항체의 생성 방법 - Google Patents

항체의 생성 방법

Info

Publication number
KR102900433B1
KR102900433B1 KR1020227002552A KR20227002552A KR102900433B1 KR 102900433 B1 KR102900433 B1 KR 102900433B1 KR 1020227002552 A KR1020227002552 A KR 1020227002552A KR 20227002552 A KR20227002552 A KR 20227002552A KR 102900433 B1 KR102900433 B1 KR 102900433B1
Authority
KR
South Korea
Prior art keywords
codon
amino acid
antibody
nucleic acid
codons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227002552A
Other languages
English (en)
Korean (ko)
Other versions
KR20220024954A (ko
Inventor
울리히 괴퍼트
슈테판 클로슈터만
카타리나 루츠
슈테판 제버
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20220024954A publication Critical patent/KR20220024954A/ko
Application granted granted Critical
Publication of KR102900433B1 publication Critical patent/KR102900433B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/60—Vectors comprising a special origin of replication system from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020227002552A 2019-06-28 2020-06-25 항체의 생성 방법 Active KR102900433B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19183171 2019-06-28
EP19183171.8 2019-06-28
PCT/EP2020/067770 WO2020260431A1 (en) 2019-06-28 2020-06-25 Method for the production of an antibody

Publications (2)

Publication Number Publication Date
KR20220024954A KR20220024954A (ko) 2022-03-03
KR102900433B1 true KR102900433B1 (ko) 2025-12-15

Family

ID=67253661

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227002552A Active KR102900433B1 (ko) 2019-06-28 2020-06-25 항체의 생성 방법

Country Status (11)

Country Link
US (1) US20220220500A1 (https=)
EP (1) EP3990484A1 (https=)
JP (2) JP7511591B2 (https=)
KR (1) KR102900433B1 (https=)
CN (1) CN113993888B (https=)
AU (1) AU2020304841B2 (https=)
BR (1) BR112021025806A2 (https=)
CA (1) CA3143803A1 (https=)
IL (1) IL289210A (https=)
MX (1) MX2021015193A (https=)
WO (1) WO2020260431A1 (https=)

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US5082767A (en) 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
CN100427603C (zh) 1999-10-04 2008-10-22 麦迪卡格公司 调控外源基因转录的方法
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
JP2006238894A (ja) * 2000-02-15 2006-09-14 Amgen Inc 線維芽細胞成長因子−２３分子およびその使用
ATE318908T1 (de) 2000-05-18 2006-03-15 Geneart Gmbh Synthetische gene für gagpol und deren verwendungen
US7879540B1 (en) 2000-08-24 2011-02-01 Promega Corporation Synthetic nucleic acid molecule compositions and methods of preparation
AU2003206684A1 (en) 2002-02-20 2003-09-09 Novozymes A/S Plant polypeptide production
US20040005600A1 (en) 2002-04-01 2004-01-08 Evelina Angov Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell
US20060024670A1 (en) 2004-05-18 2006-02-02 Luke Catherine J Influenza virus vaccine composition and methods of use
EA200700751A1 (ru) * 2004-10-05 2008-06-30 Элан Фарма Интернэшнл Лимитед Способы и композиции для улучшения продуцирования рекомбинантного белка
EP2021489A2 (en) 2006-05-30 2009-02-11 Dow Global Technologies Inc. Codon optimization method
DK2423315T3 (en) 2006-06-29 2015-04-13 Dsm Ip Assets Bv A method for obtaining enhanced polypeptide expression
LT2167540T (lt) * 2007-06-29 2018-04-25 F. Hoffmann-La Roche Ag Sunkioji grandinė mutantė, pagerinanti imunoglobulino gamybą
US7947495B2 (en) * 2007-11-01 2011-05-24 Abbott Biotherapeutics Corp. Immunoglobulin display vectors
AU2009314111A1 (en) * 2008-11-12 2010-05-20 Merck Sharp & Dohme Corp. BetaGI-IgG intron for enhanced anti-IGF1 R expression
US20100303776A1 (en) * 2009-04-16 2010-12-02 The University Of North Carolina At Chapel Hill Methods and compositions for regulated expression of multiple nucleic acids
KR20130013435A (ko) 2011-07-28 2013-02-06 차의과학대학교 산학협력단 태반-유래 줄기세포의 증식방법
CN109810188A (zh) * 2011-12-21 2019-05-28 弗·哈夫曼-拉罗切有限公司 用于克隆和表达关联抗体可变区基因区段的快速方法
EP2794878B1 (en) * 2011-12-22 2020-03-18 F.Hoffmann-La Roche Ag Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
GB2502127A (en) * 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
JP6224077B2 (ja) * 2012-04-17 2017-11-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 改変された核酸を用いてポリペプチドを発現させるための方法
SG10201913396RA (en) * 2014-02-28 2020-03-30 Ichnos Sciences SA Expression constructs and methods for selecting host cells expressing polypeptides
KR20180018659A (ko) * 2015-06-08 2018-02-21 코닝 인코포레이티드 전달이 없는 마이크로엘이디 디스플레이

Also Published As

Publication number Publication date
EP3990484A1 (en) 2022-05-04
IL289210A (en) 2022-02-01
BR112021025806A2 (pt) 2022-02-08
JP7511591B2 (ja) 2024-07-05
AU2020304841B2 (en) 2024-08-15
US20220220500A1 (en) 2022-07-14
JP2023183417A (ja) 2023-12-27
CN113993888A (zh) 2022-01-28
MX2021015193A (es) 2022-01-18
JP2022538178A (ja) 2022-08-31
CA3143803A1 (en) 2020-12-30
KR20220024954A (ko) 2022-03-03
AU2020304841A1 (en) 2021-12-23
WO2020260431A1 (en) 2020-12-30
CN113993888B (zh) 2026-01-06
JP7835713B2 (ja) 2026-03-25

Similar Documents

Publication Publication Date Title
US20100297697A1 (en) Methods for increasing protein titers
US9243053B2 (en) Heterologous intron within an immunoglobulin domain
KR20190124270A (ko) 다중특이적 항체의 생산 방법
US9708636B2 (en) Artificial introns
EP2794878B1 (en) Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
CA2865676C (en) Method for the expression of polypeptides using modified nucleic acids
CN113924314B (zh) 通过多肽链交换活化的治疗性多特异性多肽
EP2396410B1 (en) Method for producing protein
KR102900433B1 (ko) 항체의 생성 방법
US20140248665A1 (en) Novel intron sequences
JP7826509B2 (ja) 選択マーカーとしての新規グルタミン合成酵素変異体
US9249201B2 (en) Heterologous intron within a signal peptide
HK40060841B (zh) 产生抗体的方法
HK40060841A (zh) 产生抗体的方法
JP7650802B2 (ja) 抗ウサギｃｄ１９抗体および使用方法
TWI457441B (zh) 免疫球蛋白之製造
RU2780629C1 (ru) Способ получения мультиспецифических антител

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

F13 Ip right granted in full following pre-grant review

Free format text: ST27 STATUS EVENT CODE: A-3-4-F10-F13-REX-PX0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)